EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 212)
eröffnet am 29.01.04 09:28:54 von
neuester Beitrag 23.12.23 12:39:57 von
neuester Beitrag 23.12.23 12:39:57 von
Beiträge: 12.859
ID: 814.884
ID: 814.884
Aufrufe heute: 3
Gesamt: 1.588.541
Gesamt: 1.588.541
Aktive User: 0
ISIN: AU000000PVA7 · WKN: A0Q4DA
1,8250
EUR
-2,93 %
-0,0550 EUR
Letzter Kurs 03.05.18 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,40 | +184,44 | |
| 0,8000 | +45,45 | |
| 0,6099 | +25,67 | |
| 2,0600 | +24,85 | |
| 1,1600 | +16,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5008 | -9,31 | |
| 20,360 | -11,48 | |
| 3,7300 | -14,65 | |
| 23,700 | -19,52 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: SPAM
Bis Ende März wird eingereicht.beim letzten mal hat es fünf Monate gedauert.
Aber eigentlich ist anscheinend sechs Monate die Regel.
Aber eigentlich ist anscheinend sechs Monate die Regel.
Kurze Fragen:
a)Reicht Alimerea jetzt die Zulassung bis Ende März ein, oder b) gibt die FDA ihr Ergebnis bis Ende März bekannt?
Wenn a), bis wann muss dann die FDA ein Entscheidung treffen?
a)Reicht Alimerea jetzt die Zulassung bis Ende März ein, oder b) gibt die FDA ihr Ergebnis bis Ende März bekannt?
Wenn a), bis wann muss dann die FDA ein Entscheidung treffen?
pSivida Reports Updates on ILUVIEN(R) for Planned Resubmission to FDA and European Launch
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported a number of updates with respect to ILUVIEN® for chronic diabetic macular edema (DME).
Alimera announced that it intends to resubmit its New Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration (FDA) by the end of March 2013. Using data from Alimera's two previously completed pivotal Phase III clinical trials (FAME™ Study), the resubmission will focus on the safety aspects of ILUVIEN and the population of patients with chronic DME considered insufficiently responsive to available therapies, the same group for which marketing approval for ILUVIEN has been granted in various EU countries, according to Alimera. Approval in the U.S. would entitle pSivida to a $25 million milestone payment from Alimera and 20% of net profits, as defined, from U.S. sales of ILUVIEN by Alimera.
Alimera also announced that shipments of ILUVIEN to the German market are expected to begin in the second quarter of 2013 upon acceptance from the Medicine and Health products Regulatory Agency of the intended commercial batch size, a delay from Alimera's previous expectation that this would occur in the first quarter of 2013. Alimera further reported that it also expects to begin shipments to the U.K. in the second quarter of 2013 for treatment of privately insured patients.
Alimera reported the submission of a patient access scheme (PAS) for ILUVIEN for DME has been agreed to by the UK's Department of Health and is now under consideration by NICE for inclusion in its rapid review facility. NICE had previously issued final guidance that ILUVIEN is not a cost-effective treatment for chronic DME considered insufficiently responsive to available therapies. Alimera reported that under the review facility, NICE is expected to assess the impact of the PAS on ILUVIEN's cost effectiveness and determine whether an update to the final guidance is warranted.
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported a number of updates with respect to ILUVIEN® for chronic diabetic macular edema (DME).
Alimera announced that it intends to resubmit its New Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration (FDA) by the end of March 2013. Using data from Alimera's two previously completed pivotal Phase III clinical trials (FAME™ Study), the resubmission will focus on the safety aspects of ILUVIEN and the population of patients with chronic DME considered insufficiently responsive to available therapies, the same group for which marketing approval for ILUVIEN has been granted in various EU countries, according to Alimera. Approval in the U.S. would entitle pSivida to a $25 million milestone payment from Alimera and 20% of net profits, as defined, from U.S. sales of ILUVIEN by Alimera.
Alimera also announced that shipments of ILUVIEN to the German market are expected to begin in the second quarter of 2013 upon acceptance from the Medicine and Health products Regulatory Agency of the intended commercial batch size, a delay from Alimera's previous expectation that this would occur in the first quarter of 2013. Alimera further reported that it also expects to begin shipments to the U.K. in the second quarter of 2013 for treatment of privately insured patients.
Alimera reported the submission of a patient access scheme (PAS) for ILUVIEN for DME has been agreed to by the UK's Department of Health and is now under consideration by NICE for inclusion in its rapid review facility. NICE had previously issued final guidance that ILUVIEN is not a cost-effective treatment for chronic DME considered insufficiently responsive to available therapies. Alimera reported that under the review facility, NICE is expected to assess the impact of the PAS on ILUVIEN's cost effectiveness and determine whether an update to the final guidance is warranted.
Trading Spotlight
Geh mal bei Yahoo Finance auf ALIM dort kannst du ihn ganz lesen.
kann man den kompletten artikel auch lesen ohne sich zu registrieren?
Hoffentlich geben die auch einen Ausblick und sagen evtl. etwas über die FDA Entscheidung:
http://www.finanznachrichten.de/nachrichten-2013-03/26213800…
http://www.finanznachrichten.de/nachrichten-2013-03/26213800…
Egal ob Mailand oder Madrid....Hauptsache das Ding steigt jetzt.
Ach ja noch ne Bewertung:
http://www.mysmartrend.com/news-briefs/sequenom/psivida-has-…
Ach ja noch ne Bewertung:
http://www.mysmartrend.com/news-briefs/sequenom/psivida-has-…
Durchsuchen
